IVF:NASDAQINVO Fertility, Inc. Analysis

INVO Fertility, Inc. (IVF) trades at $1.64, well below its 20‑day SMA of $1.73 and the 50‑day SMA of $2.31, indicating a short‑term bearish price action, while the 200‑day SMA sits near $15.86, underscoring a long‑term downtrend. Technical signals are mixed: RSI at 38 suggests modest oversold pressure, the MACD histogram is positive (bullish signal) despite both MACD lines remaining negative, and volume is increasing, hinting at potential buyer interest. The stock exhibits extreme volatility (≈78% 30‑day) and a strongly negative beta (‑1.68), making it highly reactive to market swings and inversely correlated to broader indices.
Fundamentally, the company is distressed: revenue of $6.9 M grew 22.6% YoY, but operating margin is –93%, net earnings are negative, cash on hand ($0.36 M) is dwarfed by debt ($4.23 M), and the book value per share is –$22.34. Nonetheless, a discounted cash‑flow model assigns a fair value of $16.74, implying a theoretical upside of over 1,100%, though this rests on highly uncertain assumptions about future cash flows and successful clinical trials. The recent Nasdaq listing notice adds a material compliance risk that could trigger delisting.